Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Dec 30;75(2):439–448. doi: 10.1136/annrheumdis-2014-206305

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

MTX treatment results in the induction of AMPK target genes. HUVEC were treated with MTX 100 nM for 48 h and mRNA levels of (A) HO-1, (B) A1, and (C) UCP-2 mRNA were analysed by qRT-PCR. (D) Induction of DAF mRNA was measured after 72 h MTX treatment. Each graph represents the results of four experiments. AMPK, AMP-activated protein kinase; A1, Bcl-2-related protein A1; DAF, decay-accelerating factor; HO-1, haem oxygenase-1; HUVEC, human umbilical vein endothelial cells; MTX, methotrexate; UCP-2, uncoupling protein-2; UT, untreated. *p<0.05; **p<0.01.